HeartBeam Inc. Honored with 2025 Innovation Award for Pioneering Remote Cardiac Diagnostics Technology

HeartBeam Inc. (NASDAQ: BEAT), a leader in medical technology focused on revolutionizing cardiac care, has been recognized with the 2025 Innovation Award in Remote Cardiac Diagnostics by the Medical Device Network Excellence Awards. This prestigious accolade underscores the company's groundbreaking FDA-cleared 3D ECG technology, which facilitates clinical-grade arrhythmia diagnostics outside traditional clinical settings through a compact, cable-free device.

The technology at the heart of this achievement is HeartBeam's synthesized 12-lead ECG software, currently under FDA review. Upon receiving clearance, the company plans to commercialize this innovative solution, further solidifying its position at the forefront of remote cardiac care. The award not only highlights HeartBeam's commitment to advancing cardiac diagnostics but also adds to its growing collection of honors for leadership in the field.

HeartBeam's platform technology is designed to capture the heart's electrical signals from three dimensions, a first in the industry. This capability enables the development of portable devices that can deliver actionable cardiac insights anywhere, empowering physicians to monitor cardiac health trends, identify acute conditions, and guide patients to appropriate care outside medical facilities. With 13 U.S. and 4 international patents related to its technology, HeartBeam is redefining the future of cardiac health management.

The implications of this award and HeartBeam's technology are profound for the healthcare industry and patients worldwide. By enabling remote diagnostics, HeartBeam is addressing critical gaps in cardiac care accessibility, potentially saving lives through early detection and intervention. This innovation represents a significant step forward in personalized medicine, offering a glimpse into a future where advanced cardiac care is available anytime, anywhere.